Zioptan

(Tafluprost)

PreclinicalSmall molecule

MMeitheal

Zioptan is one of 10 small molecule programs targeting Ocular Hypertension. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[3][1]

Indication

Ocular HypertensionActive, not recruiting

Ocular HypertensionPreclinical

Active, not recruiting

Competition

Competitive Landscape

13 competitors in Ocular Hypertension

#DrugCompanyPhaseTrials

Zolymbus

AbbVie

Approved

14 2

Travatan

Novartis

Approved

8 3

Xalatan

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

19 4

Neo-Synephrine

EExela Pharma Sciences, LLC.

Approved

—5

Deltasone

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Isopto Carpine

Vyzulta

BBausch Health Americas, Inc.

Approved

1 8

Reference - LUMIGAN

AAmneal Pharmaceuticals, LLC

Phase 3

1 9

Rocklatan

CColorado Ophthalmology Associates PC

Phase 3

1 10

Zioptan

MMeitheal

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Glaucoma3 trials

Ocular Signs and Symptoms in Glaucoma Patients Switched From Latanoprost to Preservative Free Tafluprost Eye Drops

Completed·SSanten Oy·Phase 3·NCT01087671·185 enrolled

Ocular Signs and Symptoms in Glaucoma Patients Switched From Latanoprost 0.005% to Preservative Free Tafluprost Eye Drops

Completed·SSanten Oy·Phase 3·NCT00596791·150 enrolled

Switching From Preserved to Preserved-free Treatments for Glaucoma.

Unknown status·PPaolo Fogagnolo·Phase 3·NCT01433900·40 enrolled

Ocular Hypertension1 trial

Prospective, Single Center Switching Study of 0.0015% Tafluprost Ophthalmic Solution in Primary Open-angle Glaucoma and Ocular Hypertension Patients With Corneal Disorders (Switching From 0.005% Latanoprost Ophthalmic Solution)

Completed·SSanten Pharmaceutical (Taiwan) Co., LTD·N/A·NCT04737928·1 enrolled

Efficacy1 trial

24-hour Efficacy and Ocular Surface With Talfuprost and Triple Combined Therapy

Completed·—·Phase 4·NCT02802137·43 enrolled

Regulatory

FDA Approval Timeline[4]

Feb 10, 2012

ZIOPTAN

NDA NDA202514

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Tafluprost. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tafluprost compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tafluprost. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA202514). U.S. Food & Drug Administration.
[5]
FDA Orange Book — Patent and exclusivity data for Zioptan. U.S. Food & Drug Administration.
[6]
SEC EDGAR — Meitheal company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: MMeitheal

Patent Landscape[5]

Patent Cliff

May 28, 2029

Earliest patent expiration — generic entry possible after this date

Patent #Expires

10864159May 28, 2029

9999593May 28, 2029

Zioptan

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Glaucoma3 trials

Ocular Hypertension1 trial

Efficacy1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Patent Landscape[5]

Related News